26 results
Thumbnail

D1.182 - Investigation of risk factors for the development of food-induced enterocolitis syndrome in children with a history of allergic proctocolitis caused by milk

Thumbnail

D1.184 - Evaluation of recombinant GAPDH for validation as a new apple allergen in the Mexican pediatric population

Thumbnail

D1.185 - One-day oral challenge test in low risk nut allergic children

Thumbnail

D1.186 - Reggsolving the eggnigma. Characteristics and prognosis of egg FPIES in children

Thumbnail

D1.187 - The role of gut microbiota in non-specific lipid transfer protein (nsLTP) allergies: insights from 16S rRNA gene sequencing

Thumbnail

D1.188 - Diet Diversity in Early Childhood, and Prevalence of Food Allergies in Children with Autism Spectrum Disorder

Thumbnail

D1.189 - An Analysis of Adrenaline Auto-Injector distribution in the Republic of Ireland between 2019 to 2023

Thumbnail

D1.191 - Global Survey on Healthcare Provider Practices in the Primary Prevention of Food Allergy: Implementation and Regional Gaps

Thumbnail

D1.192 - Natural Course and Predictors of Cow’s Milk Allergy Resolution in an Asian Pediatric Cohort: Data from a Tertiary Care Center

Thumbnail

D1.193 - Pumpkin Seed Allergy in Children

Thumbnail

D1.194 - Phylogenetic relationships across allergenic foods to guide the risk assessment of novel food proteins

Thumbnail

D1.195 - Immunoproteomic study of pear (Pyrus communis) in mexican population

Thumbnail

D1.196 - Characterizing the detectable milk protein allergens in milk ladder foods

Thumbnail

D1.197 - Casual consumption of small amounts of peanut in children with IgE-mediated allergy is associated with outgrowing IgE-mediated peanut allergy: results of a retrospective observational study

Thumbnail

D2.351 - Relapse Rate and Risk Factors After Omalizumab Treatment in Adolescents with Chronic Spontaneous Urticaria

Thumbnail

D2.352 - Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria

Thumbnail

D2.353 - A Single Dose of Briquilimab, An Anti-Human CD117 (c-Kit) Antibody, Protects Against Relapse of Epicutaneous Allergen-Induced Dermatitis in Mice Expressing Chimeric Human/Mouse CD117

Thumbnail

D2.354 - Questionnaire survey of new treatments for atopic dermatitis

Thumbnail

D2.355 - Concurrent use of dupilumab and omalizumab in severe atopic dermatitis and severe chronic urticaria

Thumbnail

D2.356 - Real-life effectiveness of omalizumab and its impact on quality of life in patients with chronic spontaneous urticaria